Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 87c
November 4, 2021 5:05 PM EDTVir Biotechnology Inc. (NASDAQ: VIR) reported Q3 EPS of ($0.85), $0.87 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $103.6 million versus the consensus estimate of $138.25 million.
As of September 30, 2021, excluding restricted cash, the Company had approximately $939.5 million in cash, cash equivalents... More
